BioTrinity 2011 UK Innovation Posters Showcase - April 12-14, 2011
Purpose
The aim of the Innovation Poster Showcase is to foster technology transfer, relationships and partnerships between universities, biotechnology, medical device, diagnostics, pharmaceutical industries and investors from the UK and overseas. 750 delegates from 20 countries are expected, including big pharma, corporate venture funds and high-calibre venture capital investors. Pharma delegates have expressed a particular interest in what's on offer in the poster showcase.
The themes for this year's showcase are:
- Drug Discovery and Development
- Human Healthcare Diagnostics
- Medical Devices and Technology
- Platform Technology
- Vaccines
Details of BioTrinity 2010's highly successful Poster Showcase, organised by the London Technology Network, can be seen below. One of last year's poster presenters, Dr Michael McArthur, CSO of spinout Procarta Biosystems, John Innes Centre, Norwich, raised investment totalling up to £1.25 million from Morningside (Hong Kong) as a direct result from participating at the event.
Format
A Tech Transfer Officer representing the university can bring up to 3 academic scientists to present a poster of their work in the topics above to interact with bioindustry delegates. Each institution has the opportunity to present their best three pieces of IP in life sciences. A maximum of 30 academics will be allowed to present. Accepted abstracts (non-confidential) will be published online at BioTrinity for attendees. Authors of selected abstracts must present the poster in person and are suggested to be the principal investigator, or research staff with major involvement in the work.
The Poster Showcase is scheduled on the first day of the conference, Wednesday 13th April. The specific viewing time will take place at lunchtime where presenters are required to stand by their posters. Authors of the three best abstracts will be invited to give a 10 minute presentation on the afternoon of Thursday 14th April. Authors of the winning abstracts and their accompany tech transfer officer will also be automatically upgraded to a 2 day conference pass.
Application Process
An abstract template will be sent to all applicants. Please email ray.chan@obn.org.uk for details.
Abstract judging process: OBN Programme Development Team and a select committee drawn from the OBN Industry Advisory Board, which include representatives from Evotec, Manches LLP, Syntaxin, Genzyme, Prosidion, Isis Innovation, GFC Diagnostics and others.
Notification: Successful applicants from universities will be notified if they are selected to display their poster at the innovation showcase by 25th February. The best three abstracts will be selected to present on Thursday 14th April. The winners will be notified on 25th February. OBN staff will be pleased to assist with any enquiries concerning the poster session.
Deadlines
Final abstract submission deadline for competition: 17:00, 23rd February 2011
Poster Presentation Fee and Conference Access
Selected institutions will be given a special registration code to purchase one specially discounted Full Partnering Registration Pass (one day) for their Tech Transfer Officer at £599 + VAT. Price includes:
- Up to 3 Academics per University/Organisation (Non-Partnering one day passes) who are listed as an author on abstracts (one per abstract)
- Exhibition Space for up to 3 portrait A0 posters in the Innovation Poster Zone
- Continental Breakfast, Lunch, Tea & Coffee
- Access to Networking Reception (13th April)
- Access to all Workshops, Panel Discussion Sessions and Company Presentations (available to whole party)
- Access to partnering system for Tech Transfer Officer only
- The authors and their tech transfer officer of the 3 winning abstracts will have their registration upgraded from a one day pass to two days.
- Optional Gala Dinner on 12th April at £89 + VAT per delegate
- Upgrade to full conference pass available for £150 + VAT per delegate
Each institution will therefore be able to present up to three posters representing their best IP in the field of life sciences. The presentation slot offered to the three best abstracts is usually charged at up to £1,299.
On the Day Logistics
- Conference registration from 08:00 onwards
- Breakfast: 08:00 - 09:00
- Poster Mounting: 08:00 - 10:00
- Refreshments, Networking: 10:30 - 11:00
- Lunch, Networking and Poster Viewing: 12:30 - 13:30 Interact with bioindustry delegates
- Poster removal: 18:30 - 19:00
Posters must be up by 10:00 for the morning refreshments slot. Please note that both academic presenters and the accompanying Tech Transfer Officer are required to stand by their poster during the whole Presentation Time from 12:30 - 13:30 to talk to poster viewers. Therefore tech officers must not schedule private partnering meetings during this time. Posters must be removed by 19:00 at the very latest, or will be disposed of by the venue staff.
Testimonials
"I attended BioTrinity 2010 and I am very pleased to return this year to present at BioTrinity 2011, having raised investment from Morningside following our meeting at the conference. BioTrinity is the number one investment conference.", Michael McArthur, CSO and BBSRC Fellow, Procarta Biosystems, John Innes Centre
"I am not aware of another conference or meeting that promotes and facilitates, as well, interactions between the Biotech and Pharma industries, academia and funders.", Dr Geoff Boxer, LTN Business Fellow and UCL Cancer Institute
Contacts
Dr Ray Chan
OBN, Suite L/M, 11 Milton park, Abingdon OX14 4RS
T: +44 (0)845 504 9717 / F: +44 (0)1235 835843
BioTrinity 2011 Poster Showcase Participants
| Name | Institution | Poster Title |
| Dr James Baker | King's College London |
Cardiac Myosin-Binding Protein C (cMyBPC) as a Potential New Serum Biomarker of Myocardial Infarction. James Baker, Renuka Devaraj, Pierre Sicard, Johannes Reinhold, Gajen Kanaganayagam, Sakthivel Sadayappan, Mathias Gautel, Simon Redwood and Michael Marber, King's College London BHF Centre, The Rayne Institute, St Thomas' Hospital. |
| Prof. Mark Peakman | King's College London | Developing an Immune-Based Therapy for Type 1 Diabetes Using Multiple β-cell Peptides. Prof Mark Peakman, Dept. of Immunology. |
| Dr David J. Chambers | King's College London | Esmolol-adenosine Cardioplegia: a Novel 'Polarising' Cardioplegia for Improved Protection During Cardiac Surgery. Dr David J Chambers¹, Dr Hazem B Fallouh² and Prof. Jonathan C Kentish², ¹Cardiac Surgical Research and ²Cardiovascular Division, King's College London, The Rayne Institute, St Thomas' Hospital |
| Dr Paul A Lyons | University of Cambridge | The CD8 Transcriptome Predicts Prognosis in Autoimmune and Inflammatory Disease. Dr Paul A Lyons, Dr Eoin F McKinney, Dr James C Lee and Prof. Kenneth GC Smith, Cambridge Institute for Medical Research and Department of Medicine, Addenbrooke's Hospital, Cambridge. |
| Dr Daniel Wheeler | University of Cambridge | "SAFERamp" - A Safe Ampoule-Opening and Syringe Labelling Device. Dr Daniel Wheeler, Dept. of Medicine Division of Anaesthesia, Addenbrooke's Hospital, Cambridge. |
| Prof. Robert Glen | University of Cambridge | Novel Series of 5-HT1B Antagonists for Treatment of Pulmonary Arterial Hypertension. Prof. Robert Glen¹, Dr David Spring¹, Dr Prashant Kapadnis¹, Dr James Bell, Dr Robin Hiley², Dr Kirsty Mair² and Prof. Mandy MacLean³, ¹University of Cambridge, Dept. of Chemistry, Lensfield Rd., Cambridge,
²University of Cambridge, Dept. of Pharmacology, Tennis Court Rd., Cambridge and ³University of Glasgow, Research Institute of Cardiovascular and Medical Sciences, Room 417, West Medical Building. |
| Dr Spiros Linardopoulos | Institute of Cancer Research, London | Novel Dual Inhibitors of Aurora and FLT3 Kinases. Dr Spiros Linardopoulos¹, Prof. Alan Ashworth², ¹Cancer Research UK Cancer Therapeutics Unit and ²Breakthrough Breast Cancer Research Centre, The Intitute of Cancer Research, London. |
| TBC | Institute of Cancer Research, Cambridge | Potent Inhibitors of Checkpoint Kinase 1 (Chk1). The Institute of Cancer Research (ICR) Cancer Therapeutics Unit (CTU) and Sareum Ltd, London road, Pampisford, Cambridge. |
| Prof. W Nicol Keith | Senectus Therapeutics Limited | Prof. W Nicol Keith¹, Dr Masahi Narita², Prof. Dorothy Bennett³, Dr Chris Torrance⁴ and Dr Anthony Brown⁵, ¹CRUK Beatson Laboratories, University of Glasgow, ²CRUK cambridge Research Institute, University of Cambridge, ³St George's Hospital, University of London, ⁴Horizon Discoveries Ltd, Cambridge Science Park, Miton Rd., Cambridge and ⁵Cancer Research Technology Ltd., London. |
| Dr Paul J Heaney | University of Glasgow | A Novel Biosensor and Consumer Product Range for Home-use medical Screening. Dr Paul J Heaney and Dr Vincent Benoit, mode Diagnostics Ltd., Thomson Building, University of Glasgow, Gilmorehill, Glasgow. |
| Dr Margaret Anne Craig | University of Glasgow | Improving Lead Compound Selection With 50% Cost Reduction (Clyde Biosciences Preincorporation Venture). Dr Margaret Anne Craig¹, Dr Norbert Klauke², Prof. Jon Cooper², Melville Anderson, Prof. Godfrey L Smith¹, ¹Institute of Cardiovascular and Medical Sciences, ²School of Engineering, University of Glasgow. |
BioTrinity 2010 Poster Showcase Participants
| Name | Institution | Poster Title |
| Dr Rob Allaker | Queen Mary University of London |
Molecular and microbiological strategies to understand mycobacterial biology; Humoral & novel innate immune mechanisms. Drug resistance & fitness. Systems virology; Molecular genetics of antibiotic resistance. Nosocomial pathogens. Clinical microbiology |
| Dr Paul Barnett | Food & Environmental Research Agency | Inexpensive and disposable device for field detection of veterinary and plant pathogens |
| Drs Susan Seal and David Bailey | University of Greenwich | Use of next generation sequencing technology to study gene expression, DNA/RNA extraction methodologies from difficult substrates, Genetically engineering yeasts for detecting toxicants sensitively, |
| Dr Clare Sansom | Birkbeck College | X-ray crystallography of M. tuberculosis drug targets, EM structures solved include amyloid fibrils from insulin and mammalian prion protein, X-ray structures solved at Birkbeck include targets for cancer and infectious diseases, Probing mechanism of Chlamydia effectors and pathogenesis using biochemical, molecular biology and bioimaging techniques |
| Dr Paul Potter | MRC Harwell | ENU induced point mutations result in functional changes that can be identified as changes in phenotype, A wide range of screening technologies will be used to interrogate the mutant pipelines; from simple dysmorphology screens to complex behavioural and biochemical screens, Parallel Sperm and DNA archives of 10,000 mutagenised mice |
| Dr Robert Porter | National Physics Laboratory | Rapid hand held quantitative metalloimmunoassay ideal for point-of-care, Intelligent field laboratory unit in a hand-held point-of-care meter |
| Dr Michael McArthur | John Innes Centre | TFDs block expression of essential bacterial genes to prevent infection, Proprietary NCE is used for delivery of TFD to both Gram-negative and –positive bacteria |
| Dr Baptiste Lamarre | National Physics Laboratory | MS-based proteomics and conformation-responsive biosensors, Non-viral vectors and cell-penetrating systems, Tissue engineering scaffolds and nanoprobes in multiplexed POC diagnostics |
| Dr Paul Matejtschuk | National Institute of Biological Standards and Control | NIBSC has modern pharmaceutical grade filling & freeze drying facilities for the preparation of reference materials, NIBSC produce a wide range of quality control reagents for routine diagnostic serology and nucleic acid (NAT) testing |
| Dr Mark Maconochie | University of Sussex | Developing Strategies to Treat Deafness and Balance Disorders |
| Dr Bill Lindsay | The School of Pharmacy, University of London | Novel small molecules designed to specifically inhibit cancer cell proliferation have been developed and patent protected, Synthetic analogues of a natural product have been developed which decrease virulence of MRSA and render the bacterium sensitive to standard antibiotics; Two patented technologies for delivery to the GI tract: colonspecific delivery and microparticle-based |
| Dr Kal Karim | Cranfield University | Synthetic receptors, computational design of functional and "smart" materials, their synthesis and application in separation, sensing and drug development |
| Dr Geoff Boxer | UCL Cancer Institute | Tumour Models (orthotopic colorectal metastasis in liver) - Pre-clinical assessment of anti-cancer agent, localisation, efficacy and toxicity (by IHC/Fluorescence/Radioactivity); Fluorescence labelling of targeting antibodies and quantification of movement through tumour; Multi-modal Imaging of Models in vivo and ex-vivo by PET/SPECT/Photoacoustic Imaging |
| Dr Barny Cox | Queen Mary University of London | Novel apoptosis-inducing anti-cancer drugs; Potent small molecule HDAC inhibitor; Oral squamous cell carcinoma diagnostic; Pancreatic adenocarcinoma (PDAC) diagnostic |
| Drs Elizabeth Foot & Dominique Kleyn | London Genetics Ltd | Genotyping and next generation sequencing for candidate gene analysis and genome-wide screening |
